DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: PLAVIX
Summary for Tradename: PLAVIX
|
| |||||||||||
Clinical Trials for: PLAVIXEffect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery. Status: Completed Condition: Coronary Artery Disease Clopidogrel PGX Bench to Bedside Status: Completed Condition: Metabolism of Clopidogrel A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Status: Completed Condition: Healthy Clopidogrel Pharmacogenomics Project Status: Recruiting Condition: Resistance Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of Clopidogrel Status: Completed Condition: Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel; Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Status: Recruiting Condition: Diabetes Type 2; Diabetic Nephropathy; Vascular Disease Aspirin and Plavix Following Coronary Artery Bypass Grafting Status: Recruiting Condition: Coronary Graft Patency Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan) Status: Completed Condition: Coronary Artery Disease Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment. Status: Active, not recruiting Condition: Acute Myocardial Infarction Effectiveness of Clopidogrel Resinate in PCI(PRIDE) Status: Recruiting Condition: Coronary Artery Disease Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Exclusivity Expiration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET; ORAL | 020839 | Nov 17, 1997 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET; ORAL | 020839 | Nov 17, 1997 | RX | Yes | 4,847,265 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET; ORAL | 020839 | Nov 17, 1997 | RX | Yes | 5,576,328 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET; ORAL | 020839 | Nov 17, 1997 | RX | Yes | 6,429,210 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: PLAVIX
| Drugname | Dosage | Strength | RLD | Submissiondate |
| clopidogrel bisulfate | Tablets | 300 mg | Plavix | 3/4/2009 |
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc